Total cholesterol/high-density lipoprotein cholesterol ratio is a significant predictor of metabolic syndrome among people on dolutegravir-based antiretroviral therapy: A cross-sectional study in southwestern Uganda

Simple item page
dc.contributor.authorBagenda, Charles Nkubi
dc.contributor.authorNantongo, Carol
dc.contributor.authorSsemwanga, Elastus
dc.contributor.authorMugisa, Michael Junior
dc.contributor.authorOjuko, Samuel
dc.contributor.authorSempijja, Fred
dc.contributor.authorNzaramba, Daniel
dc.contributor.authorKiconco, Ritah
dc.contributor.authorSsedyabane, Frank
dc.contributor.authorMusinguzi, Benson
dc.contributor.authorAkiteng, Winnie
dc.contributor.authorTusubira, Deusdedit
dc.contributor.authorOsuwat, Lawrence Obado
dc.contributor.authorRugera, Simon Peter
dc.date.accessioned2025-09-01T20:53:09Z
dc.date.available2025-09-01T20:53:09Z
dc.date.issued2025-08-29
dc.description.abstractObjective: The total cholesterol/high-density lipoprotein cholesterol ratio is a predictor of nonalcoholic fatty liver disease—a hepatic manifestation of metabolic syndrome. This study investigated the association between total cholesterol/high-density lipoprotein cholesterol ratio and metabolic syndrome among people living with human immunodeficiency virus on dolutegravir-based antiretroviral therapy in southwestern Uganda. Methods: We conducted a secondary analysis of data obtained from a cross-sectional study of 377 adults who had been on dolutegravir-based antiretroviral therapy for at least 1 year at Ruhoko Health Centre IV, southwestern Uganda. Results: The median total cholesterol/high-density lipoprotein cholesterol ratio was significantly higher in individuals with metabolic syndrome (3.92) than in those without (2.96, p < 0.001). A statistically significant association was observed between high total cholesterol/high-density lipoprotein cholesterol ratio and metabolic syndrome (adjusted odds ratios: 2.06, 95% confidence interval: 1.08–3.91, p 1⁄4 0.028). The total cholesterol/high-density lipoprotein cholesterol ratio at an optimal cutoff of 3.30 had a significant ability (area under the curve 1⁄4 0.696, 95% confidence interval: 0.642–0.750) to differentiate participants with metabolic syndrome from those without at a sensitivity of 73% and specificity of 60%. Conclusion: The total cholesterol/high-density lipoprotein cholesterol ratio is a significant pre-dictor of metabolic syndrome and serves as a potential blood-based biomarker.
dc.identifier.citationBagenda, C. N., Nantongo, C., Ssemwanga, E., Mugisa, M. J., Ojuko, S., Sempijja, F., ... & Rugera, S. P. (2025). Total cholesterol/high-density lipoprotein cholesterol ratio is a significant predictor of metabolic syndrome among people on dolutegravir-based antiretroviral therapy: A cross-sectional study in southwestern Uganda. Journal of International Medical Research, 53(8), 03000605251370323.
dc.identifier.issn1473-2300
dc.identifier.urihttps://dir.muni.ac.ug/handle/20.500.12260/767
dc.language.isoen
dc.publisherSage
dc.subjectTotal cholesterol/high-density lipoprotein cholesterol
dc.subjectMetabolic syndrome
dc.subjectBlood-based bio-marker
dc.subjectPredictor
dc.subjectDolutegravir
dc.titleTotal cholesterol/high-density lipoprotein cholesterol ratio is a significant predictor of metabolic syndrome among people on dolutegravir-based antiretroviral therapy: A cross-sectional study in southwestern Uganda
dc.typeArticle

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Musinguzi_Article_2025_x.pdf
Size:
628.82 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
4.17 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Research Articles